StackTerminal.Health

BETA

Metabolic & Antioxidant Support

Public • 06 Apr 2026

Alpha-lipoic acid & fisetin are combined to support metabolic health & provide antioxidant benefits. Alpha-lipoic acid improves insulin sensitivity & supports metabolic function, while fisetin offers anti-aging & antioxidant support.

← Back
Buy stack
Metabolic & Antioxidant Support
metabolicantioxidantlongevity
Alpha-Lipoic Acid (ALA)
Daily with meals
MODERATE
600mg
Fisetin
Daily with meals
MODERATE
1000mg
No interactions detected
Each dose includes evidence rationale · doses personalized to your weight
AI risk assessment
Context: No wearable data
PROAI risk assessment is available with Pro.
See plans
Stack pre-check
No personal data connected — connect wearables or upload bloodwork for a personalised check
Clean
Supplements
2
Training load
Unknown
No flags
No duplication, stimulant, interaction, or recovery concerns detected.

Pre-check is rule-based, not medical advice. Consult a healthcare professional for personalised guidance.

Interaction Analysis
Pharmacokinetic + pair-level checks
Timing optimizations
Alpha-Lipoic Acid (ALA)
Take ~30 min before the intended effect window
Reaches peak plasma concentration in ~30 min. Half-life ~0.5h.
Fisetin
Take ~1h before the intended effect window
Reaches peak plasma concentration in ~1h. Half-life ~3h.

Interaction analysis is based on peer-reviewed pharmacology. PMID links go to PubMed. Not medical advice.

Supplements
2 items
Alpha-Lipoic Acid (ALA)High
Daily with meals •
Improves insulin sensitivity & supports metabolic function.
Buy ingredient →
600mg
Neuropathic symptoms in diabetic sensorimotor polyneuropathy
High
Population: Patients with type 1 or type 2 diabetes and symptomatic polyneuropathy
Study type: RCT
Dose context: 600 mg typical (range: 600–1800 mg) • Duration: 5 weeks

The SYDNEY 2 trial (n=181, 5 weeks) found all three oral ALA doses (600, 1200, 1800 mg/day) significantly reduced the Total Symptom Score versus placebo (~50% vs 32% reduction); 600 mg/day provided the optimal risk-to-benefit ratio with fewer side effects than higher doses.

Citation: Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365-70.•DOI: 10.2337/dc06-1216•https://pubmed.ncbi.nlm.nih.gov/17065669/
Neuropathic symptoms & deficits (intravenous ALA trials)
High
Population: Diabetic patients with symptomatic polyneuropathy
Study type: meta-analysis of RCTs
Dose context: 600 mg typical (range: 600–600 mg) • Duration: 3 weeks

Meta-analysis of 4 RCTs (ALADIN I, ALADIN III, SYDNEY, NATHAN II; n=1,258) found IV ALA 600 mg/day for 3 weeks significantly improved Total Symptom Scores (24.1% relative difference vs placebo) & neuropathic deficits; responder rate 52.7% vs 36.9% for placebo.

Citation: Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21(2):114-21.•DOI: 10.1111/j.1464-5491.2004.01109.x•https://pubmed.ncbi.nlm.nih.gov/14984445/
Intravenous administration; oral bioavailability is lower. Oral 600 mg/day achieves similar clinical improvements over longer duration per SYDNEY 2.
FisetinLow
Daily with meals •
Offers anti-aging & antioxidant support.
Buy ingredient →
1000mg
Senolytic activity
Low
Population: Older individuals
Study type: Systematic review
Dose context: 1000 mg typical

Senotherapy, including fisetin, may eliminate senescent cells & reduce aging-associated disability & diseases.

Citation: Balducci et al. (2024). Senotherapy, cancer, and aging. Journal of Geriatric Oncology.•DOI: 10.1016/j.jgo.2023.101671
Antioxidant activity
Low
Population: General population
Study type: Systematic review
Dose context: 1000 mg typical

Fisetin reduces reactive oxygen species & upregulates antioxidant enzymes, potentially attenuating oxidative stress.

Citation: Prem et al. (2022). Recent advances in potential of Fisetin in the management of myocardial ischemia-reperfusion injury-A systematic review. Reviews in Cardiovascular Medicine.•DOI: 10.31083/j.rcm2301023
Neuroprotection
Low
Population: Individuals with neurological diseases
Study type: Systematic review
Dose context: 1000 mg typical

Fisetin may offer neuroprotective benefits through its antioxidant & anti-inflammatory properties.

Citation: Jiang et al. (2023). The Neuroprotective Role of Fisetin in Different Neurological Diseases: a Systematic Review.•DOI: 10.1155/2014/526301
My experience with this stack
Share what worked, what did not, & help improve this protocol.

Discussion

No comments yet. Be the first to add context or ask a question.
Max 500 characters

Similar community stacks

Avoid reinventing the wheel: fork a community stack that matches your category tags, then edit it.

Browse all community stacks →
longevitymetabolicdaily

Longevity & Metabolic Health Base

by@athlete

Foundational stack aimed at mitochondrial function, insulin sensitivity, & long-term healthspan.

Omega-3 (EPA/DHA)
2000mg
Vitamin D3
50mg
Berberine
1000mg
+ 1 more supplements
New
View
metabolicweight-lossclinical-only

Peptides 💀💀💀

by@athlete

Investigational/clinical agents with strong RCT evidence in obesity-related indications (not supplements).

Retatrutide (LY-343794)
1mg
Cagrilintide
1mg
Magnesium (Glycinate)
400mg
New
View
gut-healthdailylongevity

Gut-Friendly Daily Base

by@athlete

Supports digestive resilience & long-term gut health.

Probiotics (multi-strain)
0mg
New
View